Cybin announces positive end-of-phase 2 meeting with fda for cyb003 in major depressive disorder and phase 3 program design

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a positive end-of-phase 2 meeting with the fda for cyb003, its deuterated psilocybin analog for the adjunctive treatment of major depressive disorder (“mdd”). this program will be the first ever adjunctive.
CYBN Ratings Summary
CYBN Quant Ranking